Intra-Cellular Therapies (ITCI) announced after the bell Wednesday that neither dose of ITI-007 separated from placebo on the primary endpoint in its second Phase 3 clinical trial in the treatment of schizophrenia.
from RTT - Before the Bell http://ift.tt/2dcy394
via IFTTT
No comments:
Post a Comment